Skip to main
ELV

ELV Stock Forecast & Price Target

ELV Analyst Ratings

Based on 18 analyst ratings
Buy
Strong Buy 33%
Buy 33%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Elevance Health is well-positioned as a leading provider of healthcare benefits and specialty products, with a strong local market share and a recognized brand. The company's diverse portfolio, including commercial, government, and pharmacy benefit management lines, offers significant growth potential and advantages in the increasingly important shift towards value-based care. Additionally, Elevance's recent strategic investments, disciplined capital deployment, and focus on integration and M&A, position the company for margin expansion and earnings growth in the long term. Overall, Elevance Health's strong fundamentals and potential for continued margin improvement make it an attractive stock to watch for potential investment.

Bears say

Elevance Health is facing downward pressure on its margins due to elevated costs and utilization in its Medicaid business, leading to a projected decline in membership. In addition, the company's shift towards risk-based arrangements and lower margin services in its Carelon business may also impact long-term profitability. There are also risks associated with the ACA market and potential pricing challenges. Overall, these factors contribute to a negative outlook on Elevance Health's stock as it may face challenges in maintaining its current growth trajectory and profitability in the coming years.

ELV has been analyzed by 18 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 33% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Elevance Health Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Elevance Health Inc (ELV) Forecast

Analysts have given ELV a Buy based on their latest research and market trends.

According to 18 analysts, ELV has a Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $383.56, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $383.56, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Elevance Health Inc (ELV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.